TORONTO, June 16, 2016 (GLOBE NEWSWIRE) -- Beleave Inc. (CSE:BE) (“Beleave” or the “Company”) is pleased to announce the addition of retired Lieutenant Colonel Dana Gidlow as the company’s Head of Veteran Affairs and Community Outreach.
Mr. Gidlow is President of the Toronto Police Military Veterans Association, an organization formed in 1922, which is comprised of veterans of armed conflicts either with past service in Military Units, United Nations Peace Keeping Operations or service in Reserve Units with postings to areas of conflict such as Afghanistan.
Mr. Gidlow served in the Canadian Forces Reserve Army from 1968 to 2011 when he retired as a Lieutenant Colonel after 43 years of service. In his time in the Canadian Forces, Mr. Gidlow did three tours, most recently to Afghanistan where he advised the Afghan National Police on site security.
“We are beyond pleased to be able to welcome Dana, and who better to connect with such an important demographic than someone who truly understands what it means to be a veteran,” commented Beleave CEO Roger Ferreira, “We look forward to working closely with Dana not only as we connect with our military veterans, but various groups. Dana will also play an important role in ensuring our facilities adhere to the highest in security standards.”
In addition to Mr. Gidlow’s service in the Canadian Forces, he served in the Toronto Police Service for 34 years and retired as a Supervisor in 2008. In this time, Mr. Gidlow worked on the Major Crime Unit, as a Criminal investigations Detective, and even as a Media Awareness Instructor. Mr. Gidlow was also deployed to Kosovo as an International Police Officer where among other roles, he investigated in theft and smuggling cases.
About Beleave
Beleave Inc. is a biotech company committed to becoming a licensed producer under the Marihuana for Medical Purposes Regulations (the "MMPR"). Beleave's wholly owned subsidiary First Access Medical Inc. ("FAM") has applied for a license to cultivate and sell medical marijuana pursuant to the MMPR. As of the date hereof, FAM has successfully advanced past the security clearance stage and is currently in the review stage of the licensing process. Beleave's purpose built facility is located near Hamilton, Ontario. Beleave is traded on the CSE under the symbol BE, with 17,380,823 common shares outstanding (25,541,826 on a fully diluted basis).
Cautionary Statements Regarding Forward-Looking Information
Certain statements within this press release relating to the Company constitute “forward-looking statements”, within the meaning of applicable securities laws, including without limitation, statements regarding future estimates, business plans and / or objectives, sales programs, forecasts and projections, assumptions, expectations, and/or beliefs of future performance, are "forward-looking statements". Such "forward-looking statements" involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including production and / or sales of medical marijuana, quantities of future medical marijuana production, anticipated revenues in connection with such sales, the overall projected size of the market, completion and / or expansion of production facilities, and other information that is based on forecasts of future results, estimates of production not yet determinable, and other key management assumptions. Actual results may differ materially from those expressed or implied by such forward-looking statements and involve risk and uncertainties relating to the Company's historical experience with medical marijuana operations, regulatory changes, timeliness of government approvals for the granting of permits and licenses, changes in medical marijuana prices, actual operating performance of facilities, and other uninsured risks. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Further, there can be no assurance that Beleave’s medical marijuana license application will be approved by Health Canada, or that any prospective projects in the industry will be successfully completed.